MDT

88.44

-1.53%↓

VEEV

227.74

-1.64%↓

A

113.65

-2.76%↓

HQY

87.08

-1.46%↓

PDCO

31.26

0%↓

MDT

88.44

-1.53%↓

VEEV

227.74

-1.64%↓

A

113.65

-2.76%↓

HQY

87.08

-1.46%↓

PDCO

31.26

0%↓

MDT

88.44

-1.53%↓

VEEV

227.74

-1.64%↓

A

113.65

-2.76%↓

HQY

87.08

-1.46%↓

PDCO

31.26

0%↓

MDT

88.44

-1.53%↓

VEEV

227.74

-1.64%↓

A

113.65

-2.76%↓

HQY

87.08

-1.46%↓

PDCO

31.26

0%↓

MDT

88.44

-1.53%↓

VEEV

227.74

-1.64%↓

A

113.65

-2.76%↓

HQY

87.08

-1.46%↓

PDCO

31.26

0%↓

Search

Travere Therapeutics Inc

Uždarymo kaina

17.45 -2.13

Apžvalga

Akcijų kainos pasikeitimas

24 val.

Dabar

Min

17.33

Max

18.84

Pagrindiniai rodikliai

By Trading Economics

Pajamos

-5.5M

-60M

Pardavimai

12M

75M

Pelnas, tenkantis vienai akcijai

-0.47

Pelno marža

-80.586

Darbuotojai

385

EBITDA

-4.6M

-45M

Rekomendacijos

By TipRanks

Rekomendacijos

Stiprus pirkimas

12 mėnesių prognozė

+89.73% upside

Dividendai

By Dow Jones

Kitas uždarbis

2025-05-05

Rinkos statistika

By TradingEconomics

Rinkos kapitalizacija

-138M

1.7B

Ankstesnė atidarymo kaina

19.58

Ankstesnė uždarymo kaina

17.45

Techninis įvertinimas

By Trading Central

Pasitikėjimas

Very Strong Bearish Evidence

Travere Therapeutics Inc Grafikas

Ankstesni rezultatai nėra patikimas būsimų rezultatų rodiklis.

Susijusios naujienos

2025-02-11 13:58; UTC

Pagrindinės rinkos jėgos

Travere to Seek FDA OK of Filspari in Rare Kidney Disorder FSGS; Shares Rally

Akcijų palyginimas

Kainos pokytis

Travere Therapeutics Inc Prognozė

Kainos tikslas

By TipRanks

89.73% į viršų

12 mėnesių prognozė

Vidutinis 34 USD  89.73%

Aukščiausias 47 USD

Žemiausias 22 USD

Remiantis 14 „Wall Street“ analitikais, siūlančiais 12 mėnesių tikslines Travere Therapeutics Inc kainas – Dist per pastaruosius 3 mėnesius.

Bendras įvertinimas

By TipRanks

Stiprus pirkimas

14 ratings

13

Pirkti

1

Laikyti

0

Parduoti

Techninis įvertinimas

By Trading Central

N/A / 20.98Palaikymas ir pasipriešinimas

Trumpalaikis periodas

Very Strong Bearish Evidence

Vidutinės trukmės periodas

Bearish Evidence

Ilgalaikis periodas

Weak Bullish Evidence

Finansinės naujienos

Pardavimo ir administravimo išlaidos

Veiklos sąnaudos

Ikimokestinis pelnas

Pardavimai

Pardavimo savikaina

Bendrasis pelnas iš pardavimo

Skolų palūkanų išlaidos

EBITDA

Veiklos pelnas

$

Apie bendrovę Travere Therapeutics Inc

Travere Therapeutics, Inc., a biopharmaceutical company, identifies, develops, and delivers therapies to people living with rare kidney and metabolic diseases. Its products include FILSPARI (sparsentan), a once-daily, oral medication designed to target two critical pathways in the disease progression of IgA Nephropathy (endothelin 1 and angiotensin-II); and Thiola and Thiola EC (tiopronin tablets) for the treatment of cystinuria, a rare genetic cystine transport disorder that causes high cystine levels in the urine and the formation of recurring kidney stones. The company's clinical-stage programs consist of Sparsentan, a novel investigational product candidate, which has been granted Orphan Drug Designation for the treatment of focal segmental glomerulosclerosis in the U.S. and Europe; and Pegtibatinase (TVT-058), a novel investigational human enzyme replacement candidate being evaluated for the treatment of classical homocystinuria. It has a cooperative research and development agreement with National Institutes of Health's National Center for Advancing Translational Sciences and Alagille Syndrome Alliance for the identification of potential small molecule therapeutics for Alagille syndrome. The company was formerly known as Retrophin, Inc. and changed its name to Travere Therapeutics, Inc. in November 2020. Travere Therapeutics, Inc. was incorporated in 2008 and is headquartered in San Diego, California.